Press Release<< Back
New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach
Developed in Partnership with Healthcare Professionals and Patients, Let’s Talk About LGSOC Provides Information Related to the Biology, Diagnosis, Treatment, and Patient Experience
LGSOC of the ovary, fallopian tubes, and peritoneum is a rare tumor that commonly affects younger women, with a median age of diagnosis between 45-55 years. For many patients, LGSOC symptoms and treatment side effects have a long-lasting impact on physical and mental health. To date, limited treatment options are available for LGSOC and no treatments have yet been approved by regulatory authorities specifically for the treatment of LGSOC with doctors and patients often resorting to using treatments that may have originally been developed for other tumors.
“LGSOC has only recently been classified as a separate disease as compared to the more common high-grade serous ovarian cancer (HGSOC) with different epidemiology, pathology, clinical presentation, and outcomes. Furthermore, the fact that it is rare and disproportionally affects younger women than its high-grade counterpart means we need to ensure the healthcare community is aware that this form of ovarian cancer can impact women at any age and the management approach is not the same as for other ovarian cancers,” said
LGSOC represents approximately 10% of all ovarian cancers with an estimated 1,000 to 2,000 patients diagnosed each year with more than 6,000 patients living with its impact in
“At Verastem, we are committed to providing opportunities for more education about LGSOC in partnership with the physician and patient community,” said
About Low-Grade Serous Ovarian Cancer (LGSOC)
LGSOC is a highly recurrent, chemotherapy-resistant cancer, associated with slow tumor growth and high mortality rate. An estimated 6,000 women in the
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.
+1 (781) 292-4502
Source: Verastem Oncology